PE20060465A1 - Composiciones que contienen policosanol y un inhibidor de reductasa hmg-coa - Google Patents

Composiciones que contienen policosanol y un inhibidor de reductasa hmg-coa

Info

Publication number
PE20060465A1
PE20060465A1 PE2005000582A PE2005000582A PE20060465A1 PE 20060465 A1 PE20060465 A1 PE 20060465A1 PE 2005000582 A PE2005000582 A PE 2005000582A PE 2005000582 A PE2005000582 A PE 2005000582A PE 20060465 A1 PE20060465 A1 PE 20060465A1
Authority
PE
Peru
Prior art keywords
policosanol
coa
hmg
compositions containing
reductase inhibitor
Prior art date
Application number
PE2005000582A
Other languages
English (en)
Inventor
Roger Berlin
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20060465A1 publication Critical patent/PE20060465A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE POLICOSANOL Y UN INHIBIDOR DE LA ENZIMA HMG-COA REDUCTASA DE METILGLUTARIL. DICHO POLICOSANOL COMPRENDE UNA MEZCLA DE ALCOHOLES ALIFATICOS PRIMARIOS DE CADENA RECTA CON UN LARGO DE 20 A 36 ATOMOS DE CARBONO, ENTRE LOS CUALES SE ENCUENTRAN 1-EICOSANOL, 1-DOCOSANOL, 1-TETRACOSANOL, ENTRE OTROS. EL INHIBIDOR DE HMG-COA ES UNA ESTATINA TAL COMO LOVASTATIN, ROSUVASTATIN, PRAVASTATIN, ENTRE OTRAS. EL POLICOSANOL Y LA ESTATINA SE ENCUENTRAN EN UNA PROPORCION DE ENTRE 100:1 A 0,01:1 POR PESO. TAMBIEN ESTA REFERIDA A UNA PREPARACION TRANSDERMICA CON LIBERACION SOSTENIDA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES HIPERCOLESTEROLEMICAS, COLESTEROL TOTAL, COLESTEROL LDL, ENFERMEDAD CARDIACA CORONARIA, INFLAMACION, ENTRE OTRAS
PE2005000582A 2004-05-25 2005-05-25 Composiciones que contienen policosanol y un inhibidor de reductasa hmg-coa PE20060465A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/853,578 US20050267197A1 (en) 2004-05-25 2004-05-25 Compositions containing policosanol and HMG-Co-A reductase inhibitor and their pharmaceutical uses

Publications (1)

Publication Number Publication Date
PE20060465A1 true PE20060465A1 (es) 2006-06-12

Family

ID=35426221

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000582A PE20060465A1 (es) 2004-05-25 2005-05-25 Composiciones que contienen policosanol y un inhibidor de reductasa hmg-coa

Country Status (4)

Country Link
US (1) US20050267197A1 (es)
PE (1) PE20060465A1 (es)
TW (1) TW200605865A (es)
WO (1) WO2005115381A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272770A1 (en) * 2004-04-29 2005-12-08 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050282883A1 (en) * 2004-04-29 2005-12-22 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7199126B2 (en) * 2004-04-29 2007-04-03 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7183285B2 (en) * 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
BRPI0513082A (pt) * 2004-08-06 2008-04-22 Transform Pharmaceuticals Inc formulações de fenofibrato e métodos de tratamento relacionados
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
US7642287B2 (en) * 2004-08-06 2010-01-05 Transform Pharmaceuticals, Inc. Statin pharmaceutical compositions and related methods of treatment
US20060111436A1 (en) * 2004-11-23 2006-05-25 John Griffin Compositions and treatments for modulating kinase and/or HMG-CoA reductase
ES2369787T3 (es) * 2005-02-17 2011-12-07 Chiesi Farmaceutici S.P.A. Combinaciones terapéuticas de manidipina y simvastatina.
US20070015779A1 (en) * 2005-04-29 2007-01-18 John Griffin Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
PL2018153T3 (pl) 2006-04-26 2012-09-28 Rosemont Pharmaceuticals Ltd Ciekłe kompozycje doustne
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) * 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US20100178341A1 (en) * 2008-06-11 2010-07-15 Ranbaxy Laboratories Limited BILAYERED TABLET COMPRISING NIACIN AND HMG-CoA REDUCTASE INHIBITOR
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8557236B2 (en) * 2010-02-09 2013-10-15 Vascure Natural LLC Cardiovascular support supplement and compositions and methods thereof
EP2621509A4 (en) 2010-09-15 2016-08-03 Synergy Pharmaceuticals Inc PREPARATIONS OF GUANYLATE CYCLASE-C AGONISTS AND METHODS OF USE
US9492545B2 (en) 2012-05-07 2016-11-15 Omthera Pharmaceuticals Inc. Compositions of statins and omega-3 fatty acids
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
CN114903862B (zh) * 2022-06-15 2023-08-22 湖北中古生物制药有限公司 一种多廿烷醇阿托伐他汀钙复方制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031376A (en) * 1956-10-11 1962-04-24 Levin Compositions comprising octacosanol, triacontanol, tetracosanol, or hexacosanol, andmethods employing same
US4623667A (en) * 1985-06-28 1986-11-18 Richardson-Vicks Inc. Topical treatment of skin inflammatory disorders
US4793991A (en) * 1986-01-31 1988-12-27 Slimak Karen M Hypoallergenic cosmetics, lip balms and lip sticks
US5166156A (en) * 1989-12-20 1992-11-24 Adir Et Compagnie Naphthyl piperazines useful as 5-HT1A receptor ligands
CU22229A1 (es) * 1992-09-29 1996-01-31 Dalmer Lab Sa Policosanol, una mezcla de alcoholes alifaticos primarios superiores para hipergregabilidad plaquetaria, los accidentes isquemicos, trombosis e incluso efectividad contra ulceras gastricas quimicamente inducidas y su proceso de obtencion de la caña de azucar. el tratamiento de complicaciones ateroscleroticas tales como la
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US6596776B2 (en) * 1999-06-21 2003-07-22 Hauser, Inc. High molecular weight primary aliphatic alcohols obtained from natural products and uses thereof
ATE384446T1 (de) * 2000-08-03 2008-02-15 Haerting Thomas Francis PHARMAZEUTISCHE- UND NAHRUNGSMITTELZUSAMMENZETZUNGEN MIT ßHOLZALKOHOLß UND ßHOLZSTEROLß ZUR SENKUNG DES SERUMCHOLESTERINS
WO2003020260A1 (en) * 2001-08-31 2003-03-13 Metaproteomics, Llc Arginine compositions for coordinate modification of multiple cardiovascular risk factors
CA2488498A1 (en) * 2002-06-10 2003-12-18 Elan Pharma International Limited Nanoparticulate polycosanol formulations and novel polycosanol combinations
US6890941B1 (en) * 2003-12-03 2005-05-10 Procaps S.A. Compositions containing HMG Co-A reductase inhibitors and policosanol

Also Published As

Publication number Publication date
US20050267197A1 (en) 2005-12-01
WO2005115381A2 (en) 2005-12-08
WO2005115381A3 (en) 2007-05-24
TW200605865A (en) 2006-02-16

Similar Documents

Publication Publication Date Title
PE20060465A1 (es) Composiciones que contienen policosanol y un inhibidor de reductasa hmg-coa
ES2500063T3 (es) Composición para prevenir la aparición de acontecimiento cardiovascular en paciente con riesgo múltiple
ECSP066529A (es) Derivados de tetrazol y métodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo
PE20050128A1 (es) Formulacion farmaceutica
SV2009003305A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
PE20060872A1 (es) Colorantes de cianina en el diagnostico de enfermedades proliferativas
CR11648A (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
PE20100252A1 (es) Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
AR055076A1 (es) Derivados de1,1-dioxido de 1,4-benzotiazepina,procedimiento para prepararlos,composiciones farmaceuticas que los contienen y usos en terapeutica.
PE20060276A1 (es) Composiciones que contienen policosanol, niaciana y/o derivados de niacina
EA201290596A1 (ru) Фармацевтический состав, содержащий один или более эфиров фумаровой кислоты в разлагаемой матрице
CR9014A (es) Novedosos derivados de heteroarilsulfamida benzofusionados como agentes anticonvulsionantes
UY29919A1 (es) Derivados sustituidos de 3,4-dihidroisoquinolin-1-amino-trifluoroacetato, sus composiciones farmacéuticas y aplicaciones
MA32929B1 (fr) Lactames en tant qu'inhibiteurs de bêta-sécrétase
DOP2013000130A (es) Compuestos de pirimidinona para uso en el tratamiento de las enfermedades o condiciones mediada por lp - pla2
BRPI0418147A (pt) análogos de ansamicinas contendo benzoquinona e seus métodos de uso
CL2009000241A1 (es) Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer.
CL2008000594A1 (es) Uso de compuestos derivados de heterociclos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad arterial coronaria entre otras enfermedades.
DOP2006000243A (es) Derivados de pirazina
ECSP056193A (es) Derivados sustituidos del pirrol
PE20120324A1 (es) Combinacion que comprende (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y donezepilo como moduladora de trastornos cognitivos
AR054909A1 (es) Modulacion de los receptores activados por el proliferador de peroxisomas
CR9102A (es) Derivados del acido 7-(2h-pyrazol-3-il)-3, 5 dihidroxi-heptanoico como inhibidores de la hmg co-a reductasa para el tratamiento de lipidemia
UY31403A1 (es) "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".
AR076263A1 (es) Composiciones y metodos para tratar cancer. uso.

Legal Events

Date Code Title Description
FC Refusal